Crotonoside (Synonyms: 2-Hydroxyadenosine, Isoguanine riboside, Isoguanosine, NSC 12161) |
| Catalog No.GC38412 |
Crotonoside는 FLT3와 HDAC3/6 억제제로서 급성 골수성 백혈병(AML) 연구에 사용될 수 있다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1818-71-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Crotonoside는 FLT3와 HDAC3/6 억제제로서 급성 골수성 백혈병(AML) 연구에 사용될 수 있다.
Crotonoside（50μM, 24시간）는 약 50%의 AML 세포 라인 MV4-11에서 후기 조직소멸을 유발했다[1]. Crotonoside（7.5, 15, 또는 30μM; 48시간）는 현저하게 용량 의존적으로 AML 세포 조직소멸을 유발했다[2].
Crotonoside（25, 50, 또는 100mg/kg; 20일; i.p.）는 쥐에서 콜라겐 유발 관절염（CIA）의 심각도를 개선시켰다[3]. 정상 식염수（NS）그룹에 있는 토끼와 비교했을 때 Crotonoside（4.5mg/kg, 정맥 주입）를 투여한 그룹은 아코니틴으로 인해 부정맥 시간을 효과적으로 연장하고 심실빈맥（VT）과 심실세동（VF）의 발생률을 현저하게 낮췄다[4].
References:
[1] Li YZ, Yu S, Yan PA, et al. Crotonoside exhibits selective post-inhibition effect in AML cells via inhibition of FLT3 and HDAC3/6. Oncotarget. 2017 Nov 11;8(61):103087.
[2] Ma C, Liu P, Cui S, et al. The identification of APOBEC3G as a potential prognostic biomarker in acute myeloid leukemia and a possible drug target for crotonoside. Molecules. 2022 Sep 7;27(18):5804.
[3] Lin SC, Lin CC, Li S, et al. Alleviation of collagen-induced arthritis by crotonoside through modulation of dendritic cell differentiation and activation. Plants. 2020 Nov 10;9(11):1535.
[4] Liu Z, Jia Y, Song L, et al. Antiarrhythmic effect of crotonoside by regulating sodium and calcium channels in rabbit ventricular myocytes. Life sciences. 2020 Mar 1;244:117333.
| 세포 실험 [1]: | |
세포 라인 | 급성 골수성 백혈병 (AML) 세포 라인 MV4-11 |
제조 방법 | MV4-11 세포에 Crotonoside（25, 50, 100μM）또는 0.1% DMSO를 24시간 동안 처리했습니다. 처리 후 MV4-11 세포를 수확하고 PBS로 세척한 후 Annexin V-이소시오산 형광틴（FITC）조직소멸 탐지 키트를 사용하여 조직소멸을 염색했습니다. |
반응 조건 | 25, 50alc 100μM; 16 또는24 시간 동안 |
응용 분야 | Crotonoside（50μM, 24시간）는 약 50%의 AML 세포에서 후기 조직소멸을 유발했습니다. |
| 동물 실험 [2]: | |
동물 모형 | 콜라겐 유발 관절염（CIA）쥐 모델 |
제조 방법 | Crotonoside는 10% DMSO와 90% 트리옥사노아테이트로 구성된 용매에 녹여졌습니다. 쥐는 정상 그룹, CIA대조그룹, 메토트렉서트(MTX) 처리 그룹 그리고 25, 50 또는 100mg/kg의 Crotonoside 처리 그룹으로 무작위로 네 그룹으로 나뉘어져 있습니다 (각 그룹당 n = 6). MTX (0.5mg/kg) 및 Crotonoside 치료는 첫 번째 면역화 후 21일부터 41일까지 매일 한 번씩 복강 주사로 행해졌고 솔벤트 대조 쥐는 용매를 받았습니다. |
제형 | 25, 50또는 100mg/kg; 20 일 동안; i.p. |
응용 분야 | Crotonoside는 쥐에서 콜라겐 유발 관절염（CIA）의 심각도를 개선시켰습니다. |
References: | |
| Cas No. | 1818-71-9 | SDF | |
| Synonyms | 2-Hydroxyadenosine, Isoguanine riboside, Isoguanosine, NSC 12161 | ||
| Canonical SMILES | OC[C@@H]1[C@H]([C@H]([C@H](N2C=NC(C(N)=N3)=C2NC3=O)O1)O)O | ||
| Formula | C10H13N5O5 | M.Wt | 283.24 |
| Solubility | DMSO: 25 mg/mL (88.26 mM) | Storage | Store at -20°C,protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.5306 mL | 17.6529 mL | 35.3057 mL |
| 5 mM | 0.7061 mL | 3.5306 mL | 7.0611 mL |
| 10 mM | 0.3531 mL | 1.7653 mL | 3.5306 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *